Tapentadol mediates analgesia through high-affinity, stereoselective binding to μ-opioid receptors in the central nervous system, activating inhibitory G-protein cascades that suppress ascending nociceptive transmission. Its pharmacological potency—determined by MOR binding affinity, intrinsic efficacy, and CNS penetration rate—drives therapeutic analgesic activity alongside the characteristic opioid adverse effect profile of respiratory depression, sedation, constipation, and physical dependence potential. The overlap of the respiratory depression and analgesic dose-response relationships is the primary basis for pharmacologically-based OEL calculation.
Health-based exposure limits for Tapentadol require formal periodic review as new toxicological evidence, clinical safety data, or regulatory agency assessments become available. Pharmaceutical manufacturers are expected to maintain a defined review cycle—typically every 3–5 years or triggered by significant new findings—and to update OEL, PDE, and
